News
TSBX
3.050
+6.27%
0.180
Weekly Report: what happened at TSBX last week (0506-0510)?
Weekly Report · 9m ago
Weekly Report: what happened at TSBX last week (0429-0503)?
Weekly Report · 05/06 11:16
Weekly Report: what happened at TSBX last week (0422-0426)?
Weekly Report · 04/29 11:23
Weekly Report: what happened at TSBX last week (0415-0419)?
Weekly Report · 04/22 11:11
Turnstone Biologics Corp: Current report
Press release · 04/16 14:05
Turnstone Biologics Announces Board Changes and New Chair
TipRanks · 04/16 13:02
TURNSTONE BIOLOGICS APPOINTS WILLIAM WADDILL TO ITS BOARD OF DIRECTORS
Reuters · 04/16 13:00
Weekly Report: what happened at TSBX last week (0408-0412)?
Weekly Report · 04/15 11:03
Weekly Report: what happened at TSBX last week (0401-0405)?
Weekly Report · 04/08 11:08
Weekly Report: what happened at TSBX last week (0325-0329)?
Weekly Report · 04/01 11:06
Weekly Report: what happened at TSBX last week (0318-0322)?
Weekly Report · 03/25 11:09
Turnstone Biologics GAAP EPS of -$0.73 beats by $0.25
Turnstone Biologics Corp. (TSBX) Q4 GAAP EPS of -$0.73 beats by $0.25. As of December 31, 2023, cash, cash equivalents and short-term investments were $94.8 million.
Seeking Alpha · 03/22 13:14
TSBX Stock Earnings: Turnstone Biologics Beats EPS for Q4 2023
Turnstone Biologics reported earnings per share of -73 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -86 cents. Turnstone biologics just reported results.
Investorplace · 03/22 11:52
Turnstone Biologics Q4 EPS $(0.73) Beats $(0.86) Estimate
Benzinga · 03/21 21:14
*Turnstone Biologics: Lead Program, TIDAL-01, Advancing in Phase 1 Trials With Initial Clinical Data Expected in Mid-2024 >TSBX
Dow Jones · 03/21 21:08
*Turnstone Biologics 4Q Loss/Shr 73c >TSBX
Dow Jones · 03/21 21:07
*Turnstone Biologics Expects Cash, Cash Equivalents and Short-Term Investments Will Be Sufficient to Fund Ops Into 2Q of 2025 >TSBX
Dow Jones · 03/21 21:07
Press Release: Turnstone Biologics Corp. Reports -2-
This press release discusses product candidates that are under clinical study and have not yet been approved for marketing by the U.S. Food and Drug Administration. Turnstone's product candidates are not expected to receive any regulatory approvals. The company faces other risks, including the potential for results from clinical trials to differ from expectations.
Dow Jones · 03/21 21:06
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Etao International Co (NASDAQ:ETAO) stock rose 249.4% to $0.5 during Tuesday's after-market session. The company's, Q4 earnings came out today. Taysha Gene Therapies shares moved upwards by 29.36%.
Benzinga · 03/19 21:34
Weekly Report: what happened at TSBX last week (0311-0315)?
Weekly Report · 03/18 11:07
More
Webull provides a variety of real-time TSBX stock news. You can receive the latest news about Turnstone Biologics Corp through multiple platforms. This information may help you make smarter investment decisions.
About TSBX
Turnstone Biologics Corp. is a clinical-stage biotechnology company. The Company is focused on developing new medicines to treat and cure patients with solid tumors. It is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. It is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. It is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.